Table 2 Research variables comparison based on therapy response
Variables | Therapy Response | P value | OR (95% CI) | RR (95% CI) | |
|---|---|---|---|---|---|
Chemoresistant n (%) | Chemosensitive n (%) | ||||
CD44+/CD24- immunohistochemistry | |||||
• High (≥ 10%) | 26 (81.3) | 3 (9.4) | 0.001* | 41.9 (9.5-184) | 8.01 (2.7-23.6) |
• Low (< 10%) | 6 (18.8) | 29 (90.6) | |||
CD44+/CD24- flowcytometry | |||||
• High (≥ 32692) | 25 (78.1) | 8 (25) | 0.001* | 10.7 (3.3-34.1) | 3.19 (1.7-6) |
• Low (< 32692) | 7 (21.9) | 24 (75) | |||
Ca-125 Level | |||||
• ≤ 35 | 2 (6.25) | 28 (87.5) | 0.001* | 105 (17.8-618) | 7.93 (3.14-20) |
• > 35 | 30 (93.75) | 4 (12.5) | |||
Ovarian cancer stage | |||||
• Early stage: II | 1 (3.13) | 4 (12.5) | 0.162 | 4.42 (0.5-42) | 1.68 (1-2.8) |
• Advance stage: III - IV | 31 (96.87) | 28 (87.5) | |||
Surgery type | |||||
• Optimal Debulking | 25 (84.4) | 31 (96.87) | 0.023* | 8.6 (1-75.3) | 4.43 (0.7-28.1) |
• Suboptimal Debulking | 7 (15.6) | 1 (3.13) | |||
Differentiation/cancer grade | |||||
• Good | 6 (18.75) | 7 (21.88) | 0.760 | 1.21 (0.4-4.1) | 1.09 (0.6-1.9) |
• Intermediate - Poor | 26 (81.25) | 25 (78.12) | |||
Lymph nodes metastasis | |||||
• Positive | (65.63) | 11 (34.37) | 0.012* | 3.65 (1.3-10.2) | 1.91 (1.1-3.3) |
• Negative | 11 (34.37) | 21 (65.63) | |||
Ascites | |||||
• Positive | 18 (56.25) | 14 (43.75) | 1.000 | 1 (0.3-2.7) | 1 (0.6-1.6) |
• Negative | 14 (43.75) | 18 (56.25) | |||
Tumor size | |||||
• ≤5 cm | 6 (18.8) | 8 (25) | 0.545 | 1.44 (0.4-4.7) | 1.19 (0.7-2.0) |
• >5 cm | 26 (81.2) | 24 (75) | |||
Tumor residue | |||||
• < 1cm | 25 (84.4) | 31 (96.87) | 0.023* | 8.6 (1-75.3) | 4.43 (0.7-28.1) |
• > 1cm | 7 (15.6) | 1 (3.13) | |||